Parabilis Medicines Announces Updated Phase 1/2 Data for Zolucatetide in Desmoid Tumors

Parabilis Medicines presented updated Phase 1/2 trial results for zolucatetide at the ESMO Congress 2026, showing a 72.2% objective response rate and a 100% disease control rate among patients treated with a starting dose of ≥450 mg. These results, based on data as of June 22, 2026, will guide the FDA-aligned dose selection for the upcoming PEDESTAL Phase 3 trial, set to begin in the first half of 2027, with topline results expected in 2029.